Other studies with various BRAF-mutant CRC cell lines could also show the failure of vemurafenib as monotherapy and suggest additional EGFR inhibition as a promising therapeutic approach to avoid a feedback activation of EGFR after BRAF inhibition with vemurafenib [11,56,57]. This evidence concerns the gene BRAF and colorectal carcinoma.